Research programme: anti-fibrotic therapeutics- Evotec/ PfizerAlternative Names: TargetFibrosis
Latest Information Update: 10 Sep 2015
At a glance
- Originator Evotec AG
- Developer Evotec AG; Pfizer
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis
Most Recent Events
- 09 Sep 2015 Early research in Fibrosis in USA (unspecified route)